Compounds > milnacipran
Page last updated: 2024-08-24

milnacipran and atomoxetine

milnacipran has been researched along with atomoxetine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Jovic, F; Mesleh, M; Phan, K; Tamiya, J; Vickers, T; Zhang, M1
Aparicio, A; Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Jovic, F; Phan, K; Tamiya, J; Tran, JA; Vickers, T; Zhang, M1
Bradbury, MJ; Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Johns, M; Jovic, F; Li, B; Madan, A; O'Brien, J; Pick, RR; Saunders, J; Tamiya, J; Tran, JA; Vickers, T; Wen, J; Zhang, M1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for milnacipran and atomoxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for milnacipran and atomoxetine

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Feb-15, Volume: 18, Issue:4

    Topics: Acetamides; Alkylation; Amides; Cyclopropanes; Indoles; Milnacipran; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Stereoisomerism; Structure-Activity Relationship; Vesicular Monoamine Transport Proteins

2008
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Jun-01, Volume: 18, Issue:11

    Topics: Antidepressive Agents; Combinatorial Chemistry Techniques; Cyclopropanes; Humans; Inhibitory Concentration 50; Milnacipran; Molecular Structure; Norepinephrine; Selective Serotonin Reuptake Inhibitors; Stereoisomerism; Structure-Activity Relationship

2008
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
    Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22

    Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Microsomes, Liver; Milnacipran; Models, Molecular; Molecular Structure; Molecular Weight; Neuralgia; Norepinephrine Plasma Membrane Transport Proteins; Pain Measurement; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Stereoisomerism; Structure-Activity Relationship

2008
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010